Does Targeted, Disease-Specific Public Research Funding Influence Pharmaceutical Innovation?

Journal of Policy Analysis and Management

Volumn 31, Issue 3, 2012, Pages 641-660

  Blume Kohout, Margaret E ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLASSIFICATION; CLINICAL TRIAL (TOPIC); DISEASES; DRUG DESIGN; DRUG THERAPY; ECONOMICS; FINANCIAL MANAGEMENT; FORECASTING; HEALTH CARE ORGANIZATION; HUMAN; LONGITUDINAL STUDY; MEDICAL RESEARCH; NATIONAL HEALTH ORGANIZATION; PHARMACOLOGY; STATISTICAL MODEL; STATISTICS; UNITED STATES;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DISEASE; DRUG DESIGN; DRUG THERAPY; FINANCING, GOVERNMENT; FORECASTING; HEALTH CARE RATIONING; HUMANS; LONGITUDINAL STUDIES; MODELS, ECONOMETRIC; NATIONAL INSTITUTES OF HEALTH (U.S.); PHARMACOLOGY; RESEARCH SUPPORT AS TOPIC; UNITED STATES;

EID: 84862581619     PISSN: 02768739     EISSN: 15206688     Source Type: Journal    
DOI: 10.1002/pam.21640     Document Type: Article

References (60)

1. Abrantes-Metz, R. M., Adams, C. P., & Metz, A. D. (2006). Pharmaceutical development phases: A duration analysis. Journal of Pharmaceutical Finance, Economics, & Policy, 14, 19-41.
2. Acemoglu, D., & Linn, J. (2004). Market size in innovation: Theory and evidence from the pharmaceutical industry. Quarterly Journal of Economics, 119, 1049-1090.
3. Adams, C. P., & Brantner, V. V. (2006). Estimating the cost of new drug development: Is it really $802 million? Health Affairs, 25, 420-428.
4. Akaike, H. (1992). Information theory and an extension of the maximum likelihood principle. In S. Kotz & N. L. Johnson (Eds.), Breakthroughs in statistics (Vol. 1, pp. 610-624). London: Springer-Verlag.
5. Arellano, M., & Bond, S. (1991). Some tests of specification for panel data-Monte-Carlo evidence and an application to employment equations. Review of Economic Studies, 58, 277-297.
6. Arrowsmith, J. (2011a). Trial watch: Phase II failures: 2008-2010. Nature Reviews Drug Discovery, 10, 328-329.
7. Arrowsmith, J. (2011b). Trial watch: Phase III and submission failures: 2007-2010. Nature Reviews Drug Discovery, 10, 87.
8. Berndt, E. R., Cockburn, I. M., & Grépin, K. A. (2006). The impact of incremental innovation in biopharmaceuticals: Drug utilisation in original and supplemental indications. Pharmacoeconomics, 24, 69-86.
9. Blume-Kohout, M., & Sood, N. (2008). The impact of Medicare Part D on pharmaceutical R&D. Cambridge, MA: National Bureau of Economic Research.
10. Blundell, R., Griffith, R., & Van Reenen, J. (1995). Dynamic count data models of technological innovation. The Economic Journal, 105, 333-344.
11. Blundell, R., Griffith, R., & Windmeijer, F. (2002). Individual effects and dynamics in count data models. Journal of Econometrics, 108, 113-131.
12. Cameron, A. C., & Trivedi, P. K. (1998). Regression analysis of count data. New York: Cambridge University Press.
13. Chamberlain, G. (1992). Comment: Sequential moment restrictions in panel data. Journal of Business & Economic Statistics, 10, 20-26.
14. Cincera, M. (1997). Patents, R&D, and technological spillovers at the firm level: Some evidence from econometric count models for panel data. Journal of Applied Econometrics, 12, 265-280.
15. Civan, A., & Maloney, M. T. (2006). The determinants of pharmaceutical research and development investments. Contributions to Economic Analysis & Policy, 5, article 28.
16. Cockburn, I., & Henderson, R. (1997). Public-private interaction and the productivity of pharmaceutical research. Cambridge, MA: National Bureau of Economic Research.
17. Cohen, W. M., Nelson, R. R., & Walsh, J. P. (2002). Links and impacts: The influence of public research on industrial R&D. Management Science, 48, 1-23.
18. Committee on Accelerating Rare Diseases Research and Orphan Product Development. (2011). Rare diseases and orphan products: Accelerating research and development. Washington, DC: Institute of Medicine.
19. Committee on the NIH Research Priority-Setting Process. (1998). Scientific opportunities and public needs: Improving priority setting and public input at the National Institutes of Health. Washington, DC: Institute of Medicine.
20. DiMasi, J. A. (2001). New drug development in the United States from 1963 to 1999. Clinical Pharmacology and Therapeutics, 69, 286-296.
21. DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003). The price of innovation: New estimates of drug development costs. Journal of Health Economics, 22, 151-185.
22. Dorsey, E. R., Thompson, J. P., Carrasco, M., de Roulet, J., Vitticore, P., Nicholson, S., Johnston, S.C., Holloway, R.G., Moses III, H. (2009). Financing of US biomedical research and new drug approvals across therapeutic areas. PLOS One, 4, e7015.
23. Finkelstein, A. (2004). Static and dynamic effects of health policy: Evidence from the vaccine industry. Quarterly Journal of Economics, 119, 527-564.
24. Garber, S., Gates, S. M., Blume-Kohout, M. E., Burgdorf, J. R., & Wu, H. (2011). Challenges to value-enhancing innovation in health care delivery: Commonalities and contrasts with innovation in drugs and devices. Occasional Paper No. OP-341-EMKF. Santa Monica, CA: RAND.
25. Gillum, L. A., Gouveia, C., Dorsey, E. R., Pletcher, M., Mathers, C. D., McCulloch, C. E., Johnston, S. C. (2011). NIH disease funding levels and burden of disease. PLOS One, 6, e16837. doi:10.1371/journal.pone.0016837
26. Grabowski, H. G., & Kyle, M. (2007). Generic competition and market exclusivity periods in pharmaceuticals. Managerial and Decision Economics, 28, 491-502.
27. Gross, C. P., Anderson, G. F., & Rowe, N. R. (1999). The relation between funding by the National Institutes of Health and the burden of disease. New England Journal of Medicine, 340, 1881-1887.
28. Gurmu, S., & Pérez-Sebastián., (2008). Patents, R&D and lag effects: Evidence from flexible methods for count panel data on manufacturing firms. Empirical Economics, 35, 507-526.
29. Hausman, J., Hall, B. H., & Griliches, Z. (1984). Econometric models for count data with an application to the patents-R&D relationship. Econometrica, 52, 909-938.
30. IMS. (2011). The global use of medicines: Outlook through 2015. Parsippany, NJ: IMS Institute for Healthcare Informatics.
31. Jaffe, A. B. (1989). Real effects of academic research. American Economic Review, 79, 957-970.
32. Lichtenberg, F. R. (1999). The allocation of public funds for biomedical R&D. Washington, DC: AEI Press.
33. Lichtenberg, F. R. (2007). Importation and innovation. Economics of Innovation and New Technology, 16, 403-417.
34. Mansfield, E. (1991). Academic research and industrial innovation. Research Policy, 20, 1-12.
35. Montalvo, J. G. (1997). GMM estimation of count panel data models with fixed effects and predetermined instruments. Journal of Business and Economic Statistics, 15, 82-89.
36. Montgomery, D. C., Peck, E. A., & Vining, G. G. (2001). Introduction to linear regression analysis (3rd ed.). New York: John Wiley & Sons, Inc.
37. Moses, H., Dorsey, E. R., Matheson, D. H. M., & Thier, S. O. (2005). Financial anatomy of biomedical research. Journal of the American Medical Association, 294, 1333-1342.
38. Mullahy, J. (1997). Instrumental-variable estimation of count data models: Applications to models of cigarette smoking behavior. Review of Economics and Statistics, 79, 586-593.
39. Narin, F., Hamilton, K. S., & Olivastro, D. (1997). The increasing linkage between U.S. technology and public science. Research Policy, 26, 317-330.
40. National Institutes of Health. (2008). Summary of the FY 2009 president's budget. Washington, DC: Author. Retrieved April 14, 2009, from %20of%20FY%202009%20Budget-Press%20Release.pdf.
41. Pharmaceutical Research and Manufacturers of America. (2011). Pharmaceutical industry profile 2011. Washington, DC: PhRMA.
42. Sampat, B. N., & Lichtenberg, F. R. (2011). What are the respective roles of the public and private sectors in pharmaceutical innovation? Health Affairs, 30, 332-339.
43. Spasic, I., Ananiadou, S., McNaught, J., & Kumar, A. (2005). Text mining and ontologies in biomedicine: Making sense of raw text. Briefings in Bioinformatics, 6, 239-251.
44. Stevens, A. J., Jensen, J. J., Wyller, K., Kilgore, P. C., Chatterjee, S., & Rohrbaugh, M. L. (2011). The role of public-sector research in the discovery of drugs and vaccines. New England Journal of Medicine, 364, 535-541.
45. Toole, A. A. (2007). Does public scientific research complement private investment in research and development in the pharmaceutical industry? Journal of Law and Economics, 50, 81-104.
46. Toole, A. A. (2012). The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry. Research Policy, 41, 1-12.
47. United States Senate Joint Economic Committee. (2000, May 17). The benefits of medical research and the role of the NIH. Washington, DC: Author. Retrieved September 23, 2011, from.
48. Ward, M. R., & Dranove, D. (1995). The vertical chain of research and development in the pharmaceutical industry. Economic Inquiry, 33, 70-87.
49. Windmeijer, F. (2000). Moment conditions for fixed effects count data models with endogenous regressors. Economics Letters, 68, 21-24.
50. Windmeijer, F. (2002). ExpEnd, a Gauss programme for non-linear GMM estimation of exponential models with endogenous regressors for cross section and panel data. London: Institute for Fiscal Studies, Centre for Microdata Methods and Practice.
51. Wooldridge, J. M. (1997). Multiplicative panel data models without the strict exogeneity assumption. Econometric Theory, 13, 667-678.
52. Wooldridge, J. M. (2002). Econometric analysis of cross section and panel data. Cambridge, MA: MIT Press.
53. Wooldridge, J. M. (2009). Introductory econometrics: A modern approach (4th ed.). Mason, OH: South-Western Cengage Learning.
54. World Health Organization. (2008). The global burden of disease: 2004 Update. Geneva, Switzerland: WHO.
55. Yin, W. (2008). Market incentives and pharmaceutical innovation. Journal of Health Economics, 27, 1060-1077.
56. Yoo, I., Hu, X., & Song, I.-Y. (2006, August). Integration of semantic-based bipartite graph representation and mutual refinement strategy for biomedical literature clustering. Paper presented at the KDD'06, Philadelphia, PA. ACM.
57. Allison, P. D., & Waterman, R. P. (2002). Fixed-effects negative binomial regression models. Sociological Methodology, 32, 247-265.
58. Hilbe, J. M. (2007). Negative binomial regression. New York: Cambridge University Press.
59. National Institutes of Health. (2008). NIH research portfolio online reporting tool (RePORT)-Estimates of funding for various research, condition, and disease categories (RCDC). Washington, DC: Author. Retrieved April 1, 2009, from.
60. Winkelmann, R. (2008). Econometric analysis of count data (4th ed.). Berlin: Springer.